European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the granting of conditional marketing authorization for Tepkinly (epcoritamab) as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. The final European Commission decision on this indication for Tepkinly is anticipated later this year.
Poisoning one’s political rivals has a long history. In 399 B.C., an Athenian court found Socrates guilty of “impiety and the corruption of youth” and ordered him to drink a fatal dose of hemlock.
